Clinical trials: Hepatobiliary Disorders
Nonalcoholic Fatty Liver Disease, Liver Steatosis
Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis
Nowadays, the morbidity of Nonalcoholic fatty liver disease (NAFLD) show ascending trend year by year, which has become an important public health problem in China.
- Conditions
- Nonalcoholic Fatty Liver Disease, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT03386890
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Friendship Hospital
Liver Transplantation, Liver Transplant
Effect of Preoperative Oral Carbohydrate Loading on Postoperative Outcomes in Liver Transplant Patients
The aim of the study is to evaluate the effect of preoperative oral carbohydrate loading on postoperative outcomes in liver transplant recipients.
- Conditions
- Liver Transplantation, Liver Transplant, Liver Transplant Surgery, End Stage Liver Disease
- Trial name
- NCT07519057
- Testing
- Preoperative Oral Carbohydrate Loading
- Where
- Poland
- Volunteers
- 434 people
- Sponsor
- Medical University of Warsaw
Non-alcoholic Fatty Liver Disease
A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men
This study looks at how a new study medicine called NNC0194-0499 behaves in the body of Chinese men. Three different dose levels will be tested. Participant will get only one of the three different dose levels of NNC0194-0499.
- Trial name
- NCT05742919
- Testing
- NNC0194-0499, NC0194-0499
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Plant Stanols and Liver Inflammation in Overweight and Obese Children
Obesity is associated with a variety of co-morbidities. Children with obesity are more likely to have risk factors associated with cardiovascular diseases (CVD) and CVD risk markers (e.g.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, NAFLD, NASH
- Trial name
- NCT04783116
- Testing
- Plant stanols (3g/day)
- Where
- Netherlands
- Volunteers
- 52 people
- Sponsor
- Maastricht University Medical Center
Liver Transplant; Complications, Ischemia Reperfusion Injury
Abdominal Regional Perfusion in Donation After Cardiac Death for Multi-Organ Transplantation
The main purpose of this study is to increase the pool of organs available for donation by performing ARP to recondition donation after cardiac death (DCD) organs prior to transplantation.
- Conditions
- Liver Transplant; Complications, Ischemia Reperfusion Injury, Cirrhosis, Liver Cancer
- Trial name
- NCT03946852
- Testing
- Abdominal Regional Perfusion
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Mediterranean Lifestyle Intervention in Patients With Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is considered as the hepatic manifestation of the metabolic syndrome. NAFLD is a pathologic condition which involves both hepatic steatosis and non alcoholic steatohepatitis (NASH), as…
- Trial name
- NCT01894438
- Testing
- Mediterranean lifestyle, Mediterranean Diet
- Where
- Greece
- Volunteers
- 63 people
- Sponsor
- Harokopio University
Metabolic Dysfunction-associated Steatotic Liver Disease
Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease
Muscle changes including myosteatosis are reported as highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD). Recent studies highlighted a link between muscle fat content and liver disease severity.
- Trial name
- MYO-MASLD (NCT06506513)
- Testing
- High-intensity interval training, Moderate intensity exercise training, Low intensity exercise training
- Where
- 2 sites in Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Liver Cirrhoses, Portal Hypertension Related to Cirrhosis
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity.
- Conditions
- Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
- Trial name
- OPTIMAL (NCT07058155)
- Testing
- Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- The Cleveland Clinic
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
This is a randomized, double-blind, placebo-controlled study in up to 104 patients with a diagnosis of Non-alcoholic fatty Liver disease (NAFLD) and/or Non-alcoholic steatohepatitis (NASH).
- Trial name
- EVIDENCES IV (NCT03061721)
- Testing
- Saroglitazar magnesium 1 mg, Saroglitazar magnesium 2 mg, Saroglitazar magnesium 4 mg
- Where
- 18 sites in United States
- Volunteers
- 106 people
- Sponsor
- Zydus Therapeutics Inc.
Chronic Liver Disease
BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis
This trial is a pivotal trial to validate the use of a 13 C labeled substrate called methacetin and the BreathID automatic breath testing system, for determination of cirrhosis in patients with chronic liver disease.
- Trial name
- MBT (NCT00736840)
- Testing
- c13 methacetin solution with breath analyzer
- Where
- 11 sites in United States, Israel
- Volunteers
- 414 people
- Sponsor
- Meridian Bioscience, Inc.
Fatty Liver
Monitoring Changes in Hepatic Steatosis Using Continuous Controlled Attenuation Parameter
Background: Non-alcoholic fatty liver disease (NAFLD) affects 30% of the Asian adult population and is emerging as one of the important leading causes of liver cancer and cirrhosis.
- Trial name
- NCT06203548
- Testing
- Lifestyle modification programme
- Where
- Hong Kong
- Volunteers
- 150 people
- Sponsor
- Chinese University of Hong Kong
Non-alcoholic Steatohepatitis
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants
This is a Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants.
- Trial name
- NCT05848440
- Testing
- AZD9550
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
HIV Infections
2000 HIV Human Functional Genomics Partnership Program
Background Chronic HIV infection leads to a dysregulated immune system, even when full viral suppression is achieved. HIV causes persistent immune activation, relating to an array of common non-AIDS-related diseases such as…
- Trial name
- 2000HIV (NCT03994835)
- Where
- 4 sites in Netherlands
- Volunteers
- 1,910 people
- Sponsor
- Radboud University Medical Center
Type 2 Diabetes Mellitus, Obesity
The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes
This research study is being performed to begin to determine the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss in patients and promote improvements in…
- Trial name
- TRIABETES (NCT01047735)
- Testing
- Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Pittsburgh
Liver Disease
Evaluation of EV1000™/volumeView™ for Cardiac Output Monitoring in Liver Transplantation
The investigators are trying to evaluate the agreement of cardiac output measurements taken using the specific thermistor-tipped arterial catheter ( the VolumeView ™ catheter) and the EV1000 ™ monitoring platform ( Edward…
- Trial name
- NCT02306018
- Testing
- EV1000™/volumeView™
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Samsung Medical Center
NAFLD
NAFLD in Diabetes Type 2 in Primary Care
The EPSONIP (Evaluating Prevalence and Severity Of NAFLD In Primary care) trial is a longitudinal cohort study of patients with T2DM recruited from primary health care centers in Östergötland, Sweden.
- Trial name
- EPSONIP (NCT03864510)
- Where
- 2 sites in Sweden
- Volunteers
- 317 people
- Sponsor
- Linkoeping University
Primary Biliary Cholangitis
EXerCise Intervention in cholesTatic LivEr Disease: The EXCITED Study
A prospective, single centre, single-arm, pilot study investigating the safety and efficacy of a 12-week remotely-monitored home-based exercise program in patients with refractory fatigue (based on PBC-40 Quality of Life measure)…
- Trial name
- EXCITED (NCT04265235)
- Testing
- Home-based exercise program
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- University of Birmingham
Non-alcoholic Steatohepatitis (NASH)
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
This study is intended to investigate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD2693, following subcutaneous (SC) administration of multiple ascending doses in participants with…
- Trial name
- NCT04483947
- Testing
- AZD2693
- Where
- 16 sites in United States
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Metastatic Biliary Tract Carcinoma
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Based on the facts of multiple pathways involvement in cholangiocarcinoma tumor genesis, including EGFR, Ras, Raf, VEGFR, and PDGFR, with evidence of overexpression of these proteins associated with tumor stage, prognosis and…
- Trial name
- NCT02053376
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Nathan Bahary, MD
Nonalcoholic Fatty Liver Disease (NAFLD)
Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children
CyNCh is a multi-center, placebo-controlled clinical trial of children ages 8 to 17 years with biopsy-confirmed moderate to severe nonalcoholic fatty liver disease (NAFLD).
- Trial name
- CyNCh (NCT01529268)
- Testing
- DR cysteamine bitartrate capsule
- Where
- 10 sites in United States
- Volunteers
- 169 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.